![4,4'-(1H,1'H-[2,2'-Biimidazole]-1,1'-diyl)dibenzoic acid](https://file.medchemexpress.com/product_pic/hy-w456336.gif "Click to View 4,4'-(1H,1'H-[2,2'-Biimidazole]-1,1'-diyl)dibenzoic acid Product Detail")
Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
21 Results for "
H22
" in MedChemExpress (MCE) Product Catalog:
Products (21)
21 Results for "H22" in MCE Product Catalog:
2
2 Cited Publications
Cat. No.: HY-P99136
Target:
Research Areas:
1
1 Cited Publications
Synonyms: Z-Leu-Leu-LeuB(OH)2; ZL3B
Research Areas:
MG-262 (Z-Leu-Leu-LeuB(OH)2; ZL3B) is a reversible proteasome inhibitor. MG-262 down-regulates VEGF receptor Flt-1. MG-262 inhibits cell growth and induces apoptosis in malignant cells. MG-262 induces reactive oxygen species (ROS). MG-262 can be used for anti-cancer study .
1
1 Cited Publications
Cat. No.: HY-126876
CAS No.: 1178583-19-1
Research Areas:
GL-V9 inhibits proliferation of HepG2 cell (IC50 is 35.2 μM) through induction of apoptosis and cell cycle arrest at G2/M phase. GL-V9 regulates mitochondrial membrane potential and increases the production of intracellular reactive oxygen species. GL-V9 inhibits the pentose phosphate pathway (PPP), enhances fatty acid oxidation (FAO) through activation of AMPK, and thus inhibits the metastasis of cancer cells. GL-V9 exhibits antitumor efficacy in mouse model .
Research Areas:
TDO-IN-1 is an orally active and selective inhibitor of tryptophan 2,3-dioxygenase (TDO), shows excellent selectivity over indoleamine-2,3-dioxygenase (IDO), with an IC50 value of 0.62 μM (IDO). TDO-IN-1 reverse the local immune tolerance of tumor tissue to inhibit tumor growth in vivo .
Cat. No.: HY-Y0395
CAS No.: 25487-66-5
Cat. No.: HY-161141
CAS No.: 2761180-01-0
Target:
Research Areas:
EGFR/ C-Met-in-2 (Compound H-22) is a dual inhibitor of EGFR/c-Met. EGFR/c-Met-IN-2 inhibits cell proliferation by arresting G2/M phase. EGFR/c-Met-IN-2 has antitumor activity .
Cat. No.: HY-172108
Target:
Research Areas:
TGFβRI-IN-7 (compound 16W) is a potent inhibitor of TGFβRI. TGFβRI-IN-7 inhibits SMAD2/3 phosphorylation and H22 cell viability with IC50 values of 12 and 65 nM, respectively. TGFβRI-IN-7 shows anti-tumor efficacy in a xenograft model of H22 cells, with TGI of 79.6 % .
Cat. No.: HY-W040584
CAS No.: 492-98-8
1H,1'H-2,2'-Biimidazole is a metal-organic framework (MOF).
Cat. No.: HY-144232
CAS No.: 2768083-57-2
Anticancer agent 28 shows good antitumor activity in H22 allogeneic mice in vivo. Anticancer agent 28 has inhibitory potency in K562 cells of 50 times than oridonin, and its IC50 value is 0.09 μM.
Cat. No.: HY-175459
Research Areas:
PROTAC FAK degrader 3 is a selective FAK PROTAC degrader (DC50 = 1.08 nM). PROTAC FAK degrader 3 induces FAK degradation dependent on the ubiquitin-proteasome system and its binding to FAK and CRBN. PROTAC FAK degrader 3 upregulates MHC-I gene transcription and tumor cell surface expression by inhibiting the non-catalytic activity of FAK, leading to increased antigen presentation and activation of cytotoxic CD8 T cells. PROTAC FAK degrader 3 enhances in vivo anti-tumor activity by promoting MHC-I expression and enhancing T cell activation. PROTAC FAK degrader 3 can be used in cancer research targeting FAK degradation in ovarian cancer, hepatocellular carcinoma, and other cancers .
Cat. No.: HY-139815
CAS No.: 1314556-93-8
ZYJ-34c is an orally active and potent histone deacetylase inhibitor (HDACi) with IC50s of 0.056 μM and 0.146 μM for HDAC6 and HDAC8, respectively. ZYJ-34c causes G1 phase arrest in low concentration. ZYJ-34c has antiproliferative activities. ZYJ-34c exhibits antitumor potency in MDA-MB-231 and HCT116 xenograft models and possesses antimetastatic potential in a mouse hepatoma-22 (H22) pulmonary metastasis model .
Category:
Cat. No.: HY-182447
CAS No.: 69095-83-6
Synonyms: DL111-IT
Research Areas:
Contragestazol (DL111-IT) is a non-hormonal antifertility agent. Contragestazol reduces the expression of Cyclin D1 and CDK4, increases the expression of total retinoblastoma protein (pRb), and decreases the level of hyperphosphorylated pRb. Contragestazol induces G0/G1 phase cell cycle arrest. Contragestazol inhibits embryonic development by inducing luteal cell apoptosis and reducing intrauterine polyamine levels. Contragestazol exhibits antitumor activity against prostate cancer, S180 tumor and H22 tumor. Contragestazol shows extremely potent activity in terminating early pregnancy in animals .
Cat. No.: HY-P10832
CAS No.: 1228447-26-4
Cat. No.: HY-W128191
CAS No.: 10087-64-6
Synonyms: 2,2'-Bipyrrole
1H,1'H-2,2'-Bipyrrole (2,2'-Bipyrrole) is a metal-organic framework (MOF).
Cat. No.: HY-W456336
CAS No.: 2413962-77-1
4,4'-(1H,1'H-[2,2'-Biimidazole]-1,1'-diyl)dibenzoic acid is a metal-organic framework (MOF).
Cat. No.: HY-W075088
CAS No.: 37572-50-2
Synonyms: 1,1'-Diaethyl-2,2'-biimidazol
1,1'-Diethyl-1H,1'H-2,2'-biimidazole (1,1'-Diaethyl-2,2'-biimidazol) is a metal-organic framework (MOF).
Cat. No.: HY-W112832
CAS No.: 1079311-38-8
Synonyms: 1,1-Bis(pyridin-4-ylmethyl)-2,2-bisimidazole
1,1'-Bis(pyridin-4-ylmethyl)-1H,1'h-2,2'-biimidazole (1,1-Bis(pyridin-4-ylmethyl)-2,2-bisimidazole) is a metal-organic framework (MOF).
Cat. No.: HY-184926
Target:
LYTACs Asialoglycoprotein Receptor (ASGPR) Monocarboxylate Transporter Mitochondrial Metabolism MMP Cadherin
Research Areas:
PEG9MA10-PAB10-GalMA10 is a CD147 LYTAC degrader. PEG9MA10-PAB10-GalMA10 binds to the asialoglycoprotein receptor (ASGPR) via its galactose methacrylate domain, mediating its uptake by hepatoma cells. PEG9MA10-PAB10-GalMA10 induces lysosome-dependent degradation of CD147, resulting in concurrent loss of associated MCT1 and MCT4. PEG9MA10-PAB10-GalMA10 reduces extracellular lactate levels, increases intracellular lactate accumulation, inhibits glycolytic activity, and enhances mitochondrial respiratory capacity. PEG9MA10-PAB10-GalMA10 decreases the secretion of MMP-2 and MMP-9, and upregulates the expression of E-cadherin. PEG9MA10-PAB10-GalMA10 exhibits anti-tumor efficacy in hepatoma models. PEG9MA10-PAB10-GalMA10 can be used for research on liver cancer (hepatocellular carcinoma) .
Cat. No.: HY-P991960
Target:
Research Areas:
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
